Close Menu

mitochondrial DNA

LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

The company has rededicated itself to a fully blood-based test pipeline, with its next assays focused on women's health, including endometriosis and ovarian, uterine, and cervical cancers.